Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Continuation vs Discontinuation in Conservative Treatment for Chronic Subdural Hematoma
NCT07240454Recruiting
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of aspirin in chronic subdural hematoma (CSDH) (2 arms). Primary endpoint: Recurrence or Progression of the Subdural Hematoma at 6 months. Started Oct 2025; status: recruiting.
02
Drugs
aspirin
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT07240454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07240454.